02:01:59 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaSmall Cap Stockholm
Xbrane Biopharma är verksamma inom bioteknik. Bolaget är specialiserade inom forskning och utveckling av läkemedel för behandling av kritiska sjukdomar. Idag är verksamheten inriktad mot forskning inom mikrosfärisk teknologi och inom utvecklingen av proteinmolekyler. Produkterna används vid behandling utav prostatacancer och endometrios samt av diverse sällsynta och allvarliga ögonsjukdomar. Bolagets huvudkontor ligger i Solna.


2022-05-05 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-10-29 Kvartalsrapport 2021-Q3
2021-08-13 Kvartalsrapport 2021-Q2
2021-05-07 Ordinarie utdelning XBRANE 0.00 SEK
2021-05-06 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-26 Bokslutskommuniké 2020
2020-11-13 Kvartalsrapport 2020-Q3
2020-09-22 Extra Bolagsstämma 2020
2020-08-21 Kvartalsrapport 2020-Q2
2020-06-22 Ordinarie utdelning XBRANE 0.00 SEK
2020-06-18 Årsstämma 2020
2020-05-14 Årsstämma 2020
2020-05-13 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-06-18 Extra Bolagsstämma 2019
2019-05-17 Ordinarie utdelning XBRANE 0.00 SEK
2019-05-16 Årsstämma 2019
2019-05-14 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018
2018-11-16 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-25 Ordinarie utdelning XBRANE 0.00 SEK
2018-05-14 Kvartalsrapport 2018-Q1
2018-04-03 Extra Bolagsstämma 2018
2018-02-28 Bokslutskommuniké 2017
2017-11-13 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-05-19 Ordinarie utdelning XBRANE 0.00 SEK
2017-05-18 Kvartalsrapport 2017-Q1
2017-05-18 Årsstämma 2017
2017-03-07 Kapitalmarknadsdag 2017
2017-02-27 Bokslutskommuniké 2016
2016-11-21 Kvartalsrapport 2016-Q3
2016-08-22 Kvartalsrapport 2016-Q2
2016-05-27 Ordinarie utdelning XBRANE 0.00 SEK
2016-05-27 Kvartalsrapport 2016-Q1
2016-05-26 Årsstämma 2016
2016-02-18 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2021-07-02 14:11:00

Based on the results of a company-wide employee survey Xbrane Biopharma has been officially awarded the Great Place to Work® certificate by the Great Place to Work® Institute

Solna, Sweden July 2, 2021. Xbrane Biopharma (“Xbrane”), a biosimilar developer with the aim to make biological drugs affordable for wider patient populations globally, today announces its certification to a Great Place to Work® 2021 by the independent institute Great Place to Work®, a global authority on workplace culture and leadership behaviours. The certification is primarily based on ratings provided by Xbrane employees in an anonymous survey called Trust Index™ that assesses perspectives on leadership, pride and teamwork.

“We are very pleased that Xbrane has been certified as a Great Place to Work®. We strive to become a purpose-driven organization with strong values, which I think is reflected in our high Trust Index™. This is an important foundation for the future success of the company, and to fulfil our goal - to become the most attractive employer within our field”, says Martin Åmark, CEO.

95 percent of Xbrane’s employees participated in the Great Place to Work® survey. The cornerstones of the company's culture are; “Make it happen”, “Beat yesterday”, “Impossible is nothing” and “We win as one”.

About Great Place to Work® 
Great Place to Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees around the world and used those deep insights to define what makes a great workplace. Their unparalleled benchmark data is used to recognize Great Place to Work-Certified™ companies and the Best Workplaces™ in more than 60 countries, including the 100 Best Companies to Work For® and World's Best list published annually in Fortune. Everything they do is driven by the mission to build a better world by helping every organization become a Great Place to Work for All™. To learn more, visit www.greatplacetowork.com.